April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Intraocular Pressure Spikes Using Difluprednate 0.05% for Postoperative Cataract Inflammation
Author Affiliations & Notes
  • M. M. Cable
    Discover Vision Centers, Independence, Missouri
  • Footnotes
    Commercial Relationships  M.M. Cable, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 1981. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. M. Cable; Intraocular Pressure Spikes Using Difluprednate 0.05% for Postoperative Cataract Inflammation. Invest. Ophthalmol. Vis. Sci. 2010;51(13):1981. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To report intraocular pressure spikes in a consecutive series of 100 uncomplicated postoperative cataract patients using difluprednate ophthalmic emulsion 0.05% bid after surgery.

Methods: : Retrospective chart review was performed for patients with 5mm Hg or more elevation compared to baseline intraocular patients.

Results: : In a series of 100 uncomplicated phacoemulsification patients receiving bid dosing of difluprednate, average age 74.4 years, men and women, 5% of patients responded with ocular hypertension. Of those, 100%were previously diagnosed with open angle glaucoma. Average baseline IOP was 17.8 mm Hg, average maximal IOP was 35.4 mm Hg with a range of 28-44. Average increase in IOP was 17.8 mm Hg, with an average percentage increase over baseline of 100.2%. 60% of IOP spikes were noted on POD1, 40% by POD7. Iop was managed by discontinuation of Durezol and/or addition of topical glaucoma meds. All patients responded to treatment quickly returning to baseline within 1-2 days.

Conclusions: : Difluprednate given bid in uncomplicated phacoemulsification patients can cause significant and early elevations of IOP. Reported rates of ocular hypertension in bid dosing of difluprednate is 3-4%. The rate of OHTN in this series was 5% with 100% of responders having a history of OAG. Patients with a history of OAG may be more likely to respond to difluprednate even if they are not known steroid responders.

Keywords: drug toxicity/drug effects • cataract • anterior segment 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.